anti-CD3/anti-TROP2/anti-CD28 trispecific T-cell engager (Helixon)

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug Nameanti-CD3/anti-TROP2/anti-CD28 trispecific T-cell engager (Helixon)
Drug Alias Nametriple CD28 costimulator/anti-CD3/anti-TROP2 antibody (Helixon)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD28Anti-CD3Anti-Trop-2
TargetsT-cell-specific surface glycoprotein CD28T cell surface glycoprotein CD3Tumor-associated calcium signal transducer 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHelixon Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHelixon Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A